Several studies indicated that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway were targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, leading to pathway activation. This evidence concerns the gene AKT1 and cancer.